Arsenic Trioxide

證據等級: L5

預測適應症: 10 個

Arsenic Trioxide: From Acute Promyelocytic Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Arsenic trioxide (ATO) is an established antineoplastic agent whose approved use, evident throughout the clinical trial record in this evidence pack, is acute promyelocytic leukemia (APL). Among 10 TxGNN-predicted new indications, the only one with substantial supporting evidence is Myelodysplastic Syndrome (MDS), backed by 24 clinical trials and 22 publications, including a 2023 systematic review/meta-analysis. The remaining 9 predicted indications (including the top-ranked "unclassified MDS") currently have little or no direct clinical/literature support and are rated Hold.

Quick Overview

Item	Content
Original Indication	Acute Promyelocytic Leukemia (APL) — inferred from clinical trial descriptions in the evidence pack; official indication text is a data gap (DG001)
Predicted New Indication	Myelodysplastic Syndrome (MDS)
TxGNN Prediction Score	99.91% (rank 1291 among all candidates)
Evidence Level	L2
Norway Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed original mechanism-of-action data is flagged as a blocking data gap (DG002) in this evidence pack. However, based on information consistently present across the clinical trial summaries and literature, ATO acts through generation of reactive oxygen species (ROS), activation of the mitochondrial apoptotic pathway, and inhibition of NF-κB signaling. In APL, this translates clinically into degradation of the PML-RARA fusion protein driving disease remission.

MDS and APL are both clonal myeloid bone marrow disorders characterized by abnormal, apoptosis-resistant hematopoietic precursor cells. The same oxidative-stress/apoptosis-induction mechanism that clears the malignant clone in APL is mechanistically plausible for eliminating dysplastic myeloid clones in MDS. This is reinforced by preclinical work showing ATO inhibits NF-κB and FLIP signaling specifically in MDS-derived bone marrow mononuclear cells (PMID 16105982), and by multiple completed Phase 1/2 trials combining ATO with hypomethylating agents (decitabine, azacitidine) in MDS, which report synergistic pro-apoptotic effects via endoplasmic reticulum stress and BCL2-family gene modulation.

A 2023 systematic review and component network meta-analysis (PMID 37908176) specifically evaluated ATO-containing regimens across multiple MDS trials, concluding measurable efficacy with a manageable adverse event profile — the strongest single piece of evidence supporting this repurposing signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06778187	Phase 2	Recruiting	30	Oral ATO (Arsenol®) + ascorbic acid + low-intensity therapy in untreated/relapsed TP53-mutated AML/MDS/CMML
NCT00225992	Phase 2	Terminated	N/A	IV Trisenox in MDS; evaluated hematologic response and transfusion independence
NCT00104806	Phase 2	Terminated	5	ATO + dose-escalated cholecalciferol (vitamin D) in MDS
NCT00454480	Phase 2/3	Completed	2000	Large treatment-development programme for older AML/high-risk MDS patients, including ATO-based arms
NCT02190695	Phase 2	Completed	92	Randomized: decitabine vs. decitabine+carboplatin vs. decitabine+ATO in relapsed/refractory/elderly AML and MDS
NCT00195104	Phase 1/2	Completed	87	ATO + low-dose cytarabine (ara-C) in high-risk MDS and poor-prognosis AML
NCT00003885	Phase 2	Unknown	60	ATO in relapsed/refractory acute leukemia, CML blast crisis, and myelodysplasia
NCT00671697	Phase 1	Completed	13	IV decitabine + ATO + ascorbic acid combination in MDS and AML
NCT00803530	Phase 2	Terminated	55	Multicenter study of ATO + ascorbic acid in MDS
NCT00251511	Phase 2	Terminated	60	Trisenox + thalidomide in low/intermediate/high-risk MDS (IPSS-defined)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37908176	2023	Systematic Review/Meta-analysis	Hematology (Amsterdam)	Component network meta-analysis of ATO-containing regimens for MDS; ATO effective via apoptosis induction and demethylation, optimal combinations identified
40167011	2025	Cohort Study	Hematology (Amsterdam)	Decitabine + ATO in elderly high-risk MDS: efficacy and safety in a population with limited treatment options
18282365	2007	Review (with clinical data)	Clin Lymphoma Myeloma	Reviews ATO activity across leukemias and MDS, building on established APL efficacy
20425329	2006	Clinical Trial Report	Curr Hematol Malig Rep	ATO as MDS treatment via proapoptotic, antiproliferative, antiangiogenic mechanisms, monotherapy and combination
15610661	2005	Clinical Trial Report	Curr Hematol Rep	Companion review on ATO for MDS covering the same mechanistic and clinical rationale
38816179	2024	Cohort/Immunological Study	Immunopharmacol Immunotoxicol	Comparative immunological effects of oral (realgar) vs. IV arsenic in a murine MDS model
20956016	2011	Phase 1/2 Clinical Study	Leukemia Research	ATO + low-dose cytarabine in 49 previously untreated intermediate-2/high-risk MDS patients; 17% CR rate
31775455	2019	Retrospective Clinical Study	Zhonghua Nei Ke Za Zhi	Low-dose subcutaneous decitabine + ATO in intermediate/high-risk MDS (n=11); CR/HI reported in most patients
17920679	2008	Clinical Efficacy Study	Leukemia Research	ATO + thalidomide + retinoic acid combination therapy in higher-risk MDS patients
14633782	2003	Review	Hematology ASH Education Program	Overview of MDS pathophysiology and classification, contextualizing arsenic-based treatment approaches

Norway Market Information

Arsenic trioxide is currently 未上市 (not marketed) in Norway according to this evidence pack, with 0 authorizations on record. No product license entries are available to summarize.

Cytotoxicity

Arsenic trioxide is an established antineoplastic agent (referred to as "chemotherapy" throughout the source clinical trial descriptions), warranting inclusion of this section.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (arsenical antineoplastic; induces apoptosis via ROS generation and mitochondrial pathway activation)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Among 10 TxGNN-predicted indications, only MDS is backed by substantive evidence — 24 clinical trials (including a currently recruiting Phase 2 trial and a completed randomized Phase 2 comparison) and 22 publications, anchored by a 2023 systematic review/meta-analysis (L2, S3). The other 9 candidates (unclassified MDS, refractory cytopenia of childhood, ringed sideroblastic anemia, aregenerative anemia, 5q- syndrome, Ewing sarcoma, dermatofibrosarcoma protuberans, liposarcoma, ovarian myxoid liposarcoma) remain at L3–L5 with sparse or mismatched evidence and should stay on Hold.

To proceed, the following is needed:

TFDA/manufacturer package insert to resolve the blocking data gap (DG001: warnings, contraindications)
Confirmed original MOA documentation (DG002) to formally validate the mechanistic bridge to MDS
Norway market entry/import pathway assessment, given current non-marketed status
Prospective, MDS-specific randomized controlled trial data (existing trials are largely small, terminated, or combination-therapy designs) to move evidence level from L2 toward L1
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.